aid: forty-seven
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven.png
name: Forty Seven *
description: 'Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to
  commercialize CD47 immune-evasion research licensed from Stanford University (Irv Weissman and colleagues).
  Its lead program was magrolimab, a monoclonal antibody targeting CD47 — the "do not eat me" signal tumor
  cells use to evade macrophage-mediated killing — studied in myelodysplastic syndrome (MDS), acute myeloid
  leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired by
  Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to
  gilead.com. As a clinical-stage therapeutics company it exposes no public developer API surface.'
url: https://raw.githubusercontent.com/api-evangelist/forty-seven/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Immuno-Oncology
- Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/forty-seven-domain-security.yml
- type: Website
  url: http://fortyseveninc.com
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence